“Physician office labs and urgent care centers are on the front lines of respiratory illness diagnosis. With the QUICKVUE Influenza + SARS Test, we’re equipping healthcare providers with a reliable, affordable and efficient tool to differentiate between COVID-19 and influenza in minutes,” said Tammi Ranalli, PhD, Senior Vice President, Molecular Diagnostics and Point of Care Business Units, QuidelOrtho. “This innovation reflects QuidelOrtho’s commitment to supporting healthcare professionals with cost-effective solutions that streamline clinical decisions and help manage seasonal surges in respiratory infections.”

The launch of the QUICKVUE Influenza + SARS Test expands QuidelOrtho’s portfolio of respiratory solutions, including the SOFIA^™ 2 Flu + SARS Antigen FIA, by offering a visually read option alongside QuidelOrtho’s instrumented version and reinforces QuidelOrtho’s market leadership in point-of-care respiratory testing. The QUICKVUE Influenza + SARS Test is available in the United States through QuidelOrtho’s existing distribution channels and is not intended for in-home use.